CONTACT US   |  (864) 397-5101

Clemson University researchers investigate new approach to fighting breast cancer

Compliments of Greenville Journal

A Clemson University study could lead to new immunotherapy for breast cancer. The study, according to the university, provides the foundation of using cells in our bodies to target cancer cells.

Clemson researchers have used the immune system’s natural killer cells — which the body uses to fight off certain types of infections — to go after the breast cancer cells by bridging the two cells with a fusion of proteins the researchers developed.

“The idea is to use this bifunctional protein to bridge the natural killer cells and breast cancer tumor cells,” said Yanzhang “Charlie” Wei, a professor in the College of Science’s Department of Biological Sciences. “If the two cells are brought close enough together through this receptor ligand connection, the natural killer cells can release what I call killing machinery to have the tumor cells killed.”

Breast cancer kills 43,000 women each year in the U.S., according to the American Cancer Society and one in eight women and one in 1,000 men will develop invasive breast cancer.

“Very simply, cancer is uncontrolled cell growth. Some cells will become abnormal and have the potential to become cancer,” Wei explained. “The immune system can recognize these abnormal cells and destroy them before they become cancer cells. Unfortunately for those who develop cancer, the immune system is not working very well because of gene mutations and environmental factors. The result is that the cancer cells won the fight between the immune system and the tumors.”

Clemson’s researchers focused on triple-negative breast cancer, the most lethal type of breast cancer, and prolactin receptors.

Read the full article by clicking here…

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.